T-Cells

Janssen has submitted a marketing authorisation application (MAA) seeking approval of talquetamab in Europe for the treatment of patients with relapsed or refractory multiple myeloma (RRMM).   Talquetamab is an investigational, off-the-shelf, bispecific T-cell engager antibody targeting both GPRC5D, a novel drug target that is on some normal cells but overexpressed on myeloma cells, and CD3 […]

Triumvira Immunologics has revealed positive clinical data from its ongoing TACTIC‑2 Phase I/II trial of TAC01-HER2 in patients with human epidermal growth factor receptor 2 (HER2) positive solid tumours.  These interim data demonstrate that TAC01-HER2 is well-tolerated and clinical activity was observed in the two higher dosing cohorts, with a 67% disease control rate in cohort […]

An experimental therapeutic cancer vaccine induced immune system responses that led to significant tumour regression in mice, according to investigators from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.    The researchers found that intravenous (IV) administration of the vaccine SNAPvax boosted the number of cytotoxic T cells […]

As experimental data becomes bigger and more complex, scientists are challenged to make discoveries faster, consistently document and analyse their work, and easily collaborate across an organisation and with external partners. Electronic lab notebooks (ELN) provide access to all collaborators 24/7, wherever they are and whether they are employees or at contract organisations. If an […]

Mouse models with human immune cell engraftment provide platforms to evaluate compounds to treat a variety of human diseases. Humanised PBMC (hu-PBMC) mice feature quick engraftment of adult peripheral blood mononuclear cells and enable short-term studies requiring mature human T cells. Hu-PBMC mice are used as in vivo models to study and evaluate compounds for […]

This whitepaper, brought to you by The Jackson Laboratory will teach: The benefits of the JAX NSGTM-MHC I/II KO mouse platform humanised with pre-characterised PBMCs How this platform can support a wide range of immunological studies, especially those containing T cells responses The versatility of this platform to various research disciplines

A study led by LSU Health New Orleans cancer researchers describes a novel therapeutic strategy to overcome tumour-induced immunosuppression. For the first time, the research team identified a critical immunosuppressive pathway and a promising approach to intervene, protecting the ability of T-cells to attack cancer cells. Results are published in Frontiers in Immunology. “Immunotherapy is […]

Tokyo-based Takeda Pharmaceutical has optioned to acquire Adaptate Biotherapeutics, a UK company focused on developing antibody-based therapeutics for the modulation of variable delta 1 (Vδ1) gamma delta (γδ) T cells.   The acquisition   Takeda will obtain Adaptate’s antibody-based γδ T cell engager platform, including pre-clinical candidate and discovery pipeline programmes. Adaptate’s γδ T cell engagers are designed to specifically modulate γδ T cell-mediated immune responses at tumour sites while sparing […]

A study from researchers in the Perelman School of Medicine at the University of Pennsylvania has shown that an experimental immunotherapy can temporarily reprogramme patients’ immune cells to attack a specific target via only a single injection of mRNA, similar to the mRNA-based Covid-19 vaccines.  Context  The researchers, whose work is published in Science, demonstrated the new approach with an […]

Not only is there is a severe lack of effective T-cell lymphoma (TCL) treatments, according to GlobalData, but the data and analytics company does not expect any significant solutions to appear in the next decade.  Context  According to GlobalData, one key unmet need is found in the cutaneous TCL (CTCL) subtype. Early-stage CTCL has a favourable prognosis and is […]